-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $45

Benzinga·03/05/2026 19:34:45
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $44 to $45.